EBS
Emergent Biosolutions Inc
NYSE: EBS · HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC
$8.23
+3.00% today
Updated 2026-04-30
Market cap
$414.70M
P/E ratio
8.63
P/S ratio
0.56x
EPS (TTM)
$0.93
Dividend yield
—
52W range
$5 – $14
Volume
0.9M
WallStSmart proprietary scores
55
out of 100
Grade: C+
Hold
Investment rating
2.0
Growth
F6.0
Quality
B4.5
Profitability
C10.0
Valuation
A+4/9
Piotroski F-Score
Moderate
1.3
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →206 stocks currently score above 75
Price targets
Analyst target
$12.00
+45.81%
12-Month target
$6.47
-21.39%
Intrinsic (DCF)
$42.90
Margin of safety
+74.29%
0 Strong Buy2 Buy0 Hold0 Sell0 Strong Sell
Price chart
X-Ray snapshot
Strengths
+ Free cash flow $73.80M — positive
+ 74.29% below intrinsic value
Risks
- Altman Z 1.28 — distress zone
- Revenue declining -23.60% QoQ
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $1.12B | $1.05B | $1.04B | $742.90M | $742.90M |
| Net income | $-223.80M | $-760.50M | $-190.60M | $52.60M | $-54.60M |
| EPS | — | — | — | — | $0.93 |
| Free cash flow | $-149.90M | $-257.90M | $35.80M | $156.80M | $73.80M |
| Profit margin | -19.97% | -72.48% | -18.26% | 7.08% | 7.08% |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-04-01 | WILLIAMS, PAUL ANTHONY | Sale | 4,000 | $8.44 |
| 2026-03-05 | WILLIAMS, PAUL ANTHONY | Sale | 9,397 | $8.44 |
| 2026-03-05 | PERL, JESSICA | Sale | 6,465 | $8.44 |
Peer comparison
Smart narrative
Emergent Biosolutions Inc trades at $8.23. representing a P/E of 8.63x trailing earnings. Our Smart Value Score of 55/100 indicates the stock is fair. The company scores 4/9 on the Piotroski F-Score. With an Altman Z-Score of 1.28, it sits in the distress. TTM revenue stands at $742.90M. with profit margins at 7.08%. Our DCF model estimates intrinsic value at $42.90.
Frequently asked questions
What is Emergent Biosolutions Inc's stock price?
Emergent Biosolutions Inc (EBS) trades at $8.23.
Is Emergent Biosolutions Inc overvalued?
Smart Value Score 55/100 (Grade C+, Hold). DCF value $42.90.
What is the price target of Emergent Biosolutions Inc (EBS)?
The analyst target price is $12.00, representing +45.8% upside from the current price of $8.23.
What is the intrinsic value of Emergent Biosolutions Inc (EBS)?
Based on our DCF model, intrinsic value is $42.90, a +74.3% margin of safety versus $8.23.
What is Emergent Biosolutions Inc's revenue?
TTM revenue is $742.90M.
Piotroski F-Score?
4/9 — moderate financial health.
Altman Z-Score?
1.28 — distress.
Company info
SectorHEALTHCARE
IndustryDRUG MANUFACTURERS - SPECIALTY & GENERIC
CountryUSA
ExchangeNYSE
CurrencyUSD
Quick metrics
P/S ratio0.56x
ROE10.50%
Beta2.36
50D MA$8.80
200D MA$9.57
Shares out0.05B
Float0.05B
Short ratio—
Avg volume0.9M
Performance
1 week-3.14%
1 month-0.25%
3 months-31.43%
YTD-35.03%
1 year—
3 years—
5 years—